Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TScan Therapeutics, Inc. - Common Stock (NQ:TCRX)

1.270 -0.110 (-7.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 364,656
Open 1.400
Bid (Size) 1.200 (30)
Ask (Size) 1.490 (50)
Prev. Close 1.380
Today's Range 1.260 - 1.460
52wk Range 1.280 - 9.690
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience 
From TScan Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-58.8%
-58.8%
1 Month
-31.2%
-31.2%
3 Month
-57.7%
-57.7%
6 Month
-74.5%
-74.5%
1 Year
-84.1%
-84.1%

More News

Read More
Breaking Down TScan Therapeutics: 4 Analysts Share Their Views
Via Benzinga
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
The Analyst Landscape: 5 Takes On TScan Therapeutics
Via Benzinga
Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Is TScan Therapeutics Stock Gaining Today?
Via Benzinga
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
Via Benzinga
The Analyst Landscape: 7 Takes On TScan Therapeutics
Via Benzinga
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in Upcoming Investor Conferences
From TScan Therapeutics, Inc.
Via GlobeNewswire
TCRX Stock Earnings: TScan Therapeutics Meets EPS, Misses Revenue for Q2 2024
Via InvestorPlace
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Updates to its Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is TScan Therapeutics, Inc. - Common Stock publicly traded?
Yes, TScan Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does TScan Therapeutics, Inc. - Common Stock trade on?
TScan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for TScan Therapeutics, Inc. - Common Stock?
The ticker symbol for TScan Therapeutics, Inc. - Common Stock is TCRX on the Nasdaq Stock Market
What is the current price of TScan Therapeutics, Inc. - Common Stock?
The current price of TScan Therapeutics, Inc. - Common Stock is 1.270
When was TScan Therapeutics, Inc. - Common Stock last traded?
The last trade of TScan Therapeutics, Inc. - Common Stock was at 04/01/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.